Dynamic contrast-enhanced MRI (DCE-MRI) is a promising technique for assessing the response of tumor vasculature to anti-vascular therapies. Multi-agent DCE-MRI employs a combination of low and high molecular weight contrast agents, which potentially improves the accuracy of estimation of tumor hemodynamic and vascular permeability parameters. In this study, we employed multi-agent DCE-MRI to assess changes in tumor hemodynamics and vascular permeability after vascular-disrupting therapy. Multiagent DCE-MRI (sequential injection of G5 dendrimer, G2 dendrimer, and Gd-DOTA) was performed in tumor-bearing mice before, 2 h and 24 h after treatment with vascular disrupting agent DMXAA or placebo. Constrained DCE-MRI gamma capillary transit time modeling was employed to estimate flow F, blood volume fraction v b , mean capillary transit time t c , bolus arrival time t d , extracellular extravascular fraction v e , vascular heterogeneity index α -1 (all identical between agents) and extraction fraction E (reflective of permeability) and transfer constant K trans (both agent-specific) in perfused pixels. F, v b , and α -1 decreased at both time points after DMXAA, while t c increased. E (G2 and G5) showed an initial increase after which both parameters restored. K trans (G2 and Gd-DOTA) decreased at both time points after treatment. In the control, placebo-treated animals, only F, t c , and K trans Gd-DOTA showed significant changes. Histological perfused tumor fraction was significantly lower in DMXAA-treated versus control animals. Our results show how multi-agent tracer-kinetic modeling can accurately determine the effects of vascular-disrupting therapy, by separating simultaneous changes in tumor hemodynamics and vascular permeability.
Introduction
During early development of anti-vascular cancer drugs, a number of treatment effects are commonly investigated, including the mechanism of drug action, required dose, optimal therapy scheduling, and therapeutic efficacy (1, 2) . Functional imaging techniques can provide quantitative imaging biomarkers to enable early assessment of treatment effects. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), predominantly using low molecular weight contrast agents, is widely applied in both preclinical and clinical studies for noninvasive and longitudinal monitoring of antivascular therapies (1) (2) (3) . Tracer-kinetic modeling can be performed to calculate pharmacokinetic parameters that reflect microvascular functionality (4) (5) (6) . One of the most commonly used tracer-kinetic parameters is the transfer constant K trans from the model introduced by Tofts and Kermode (hereafter named the Tofts model), which describes the transfer rate of contrast material from the intravascular space into the tumor interstitial space (7) (8) (9) . Typically, a reduction in K trans is observed after antivascular therapy, providing useful information on therapeutic effects (1, 2) . However, K trans is a composite measure that is influenced by both blood flow and microvascular permeability (10) . These effects can often not be separately determined, since many anti-vascular therapies induce changes in both of these parameters. As an example, vascular targeting therapies can cause increased microvascular permeability due to vascular disruption along with decreased blood flow due to vascular collapse and hemorrhage (11) (12) (13) . Several studies have shown that macromolecular contrast agents may be more sensitive to changes in microvascular permeability and blood volume (14, 15) and that low molecular weight and macromolecular agents could be combined to Research. on February 7, 2019. © 2018 American Association for Cancer cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Recently we employed a multi-agent DCE-MRI approach, in which contrast agents of various molecular weight [generation 5 (G5) and generation 2 (G2) poly(propolyene imine) (PPI) dendrimers functionalized with Gd-DOTA moieties and low-molecular weight contrast agent Gd-DOTA] were sequentially injected within one imaging session in non-treated tumor-bearing mice (19) . Simultaneous modeling of the multi-agent DCE-MRI data was performed, for which a number of hemodynamic parameters, including blood flow, were constrained to be identical between the different boluses, whereas tracer-kinetic parameters related to microvascular permeability were separately determined for each agent. It was demonstrated that the hemodynamic parameters could be separately determined from vascular permeability using this approach. In addition, a contrast agent size-dependent decrease in the extraction fraction was measured, reflecting the lower degree of vascular permeability for macromolecular contrast agents. It was hypothesized that this approach can be used to evaluate the various changes in these tracer-kinetic parameters upon treatment targeting the vasculature.
The purpose of the present study was to apply this new multi-agent DCE-MRI method in a therapeutic setting and investigate whether it can provide a detailed assessment of changes in both hemodynamic parameters and microvascular permeability after vascular disrupting therapy of tumors in mice with the model drug DMXAA. 
Study design
Baseline MRI measurements were performed 1 day before either anti-vascular treatment (n=13) or placebo treatment (n=16). Subsequently, mice were randomly assigned to one of these treatment groups. Mice in the anti-vascular treatment group were intraperitoneally injected with the vascular disrupting agent 5,6-Dimethylxanthenone-4acetic acid (DMXAA, Sigma-Aldrich, St. Louis, MO, USA), freshly prepared at a dose of 20 mg/kg DMXAA dissolved in 5% sodium bicarbonate in ultrapure water (0.5 mg DMXAA / 100 µL). This agent was used as a model therapeutic agent, since the vascular shutdown by DMXAA is known to result from increased permeability (20) . Mice in the placebo treatment group were intraperitoneally injected with an equivalent volume of 5% sodium bicarbonate in ultrapure water. At 2 h after either DMXAA (n=13) or Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 6 placebo (n=16) treatment, mice underwent post-treatment MRI measurements. After the 2 h post-treatment MRI measurements, some of the animals (DMXAA n=6, placebo n=8) were sacrificed. The remaining animals additionally underwent MRI at 24 hours after DMXAA (n=7) or placebo (n=8) treatment and were subsequently sacrificed.
Contrast agents for multi-agent DCE-MRI
Multi-agent DCE-MRI measurements were performed using contrast agents with a range of molecular weights. Modified PPI dendrimers, functionalized with Gd-DOTA moieties Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 9, 2018; DOI: 10.1158/0008-5472. CAN-17-2569 MRI relaxivity values of GdDOTA, G2 and G5). The dendrimer-based contrast agents were dissolved in phosphate-buffered saline. For contrast agent administration, an infusion line was filled with equal volumes of the G5 dendrimer, G2 dendrimer and Gd-DOTA (at a concentration of 125 mM, ~0.1 mmol/kg), separated by equal volumes of saline. Small air bubbles between each volume prevented mixing of the agents. The gadolinium concentrations of the solutions used in the in vivo experiments were determined with inductively coupled plasma-optical emission spectrometry and the injected volumes were corrected for small differences in the actual concentration.
MRI acquisition and analysis

Animal preparation
Mice were anesthetized using isoflurane (3% for induction and 1-2% for maintenance) in medical air (at a flow rate of 0.4 L/min). A tail vein catheter for contrast agent injections was placed, after which the mice were positioned in a custom made cradle, equipped with an anesthesia mask and warm water circuit to maintain body temperature at 37°C. MRI measurements were performed with a 7T Bruker BioSpec 70/30 USR (Bruker BioSpin MRI GmbH, Ettlingen, Germany) equipped with a 1H 59/35 (outer/inner diameter in mm) circular polarized MRI transceiver volume coil (Bruker BioSpin MRI GmbH, Ettlingen, Germany). During MRI measurements, respiration rate was monitored using a balloon pressure sensor and temperature with a rectal temperature probe. 
Multi-agent tracer-kinetic modeling
Details of the multi-agent tracer-kinetic modeling have been described in our previously published work (19) . In short, arterial input functions (AIF) were determined for each agent separately using the Monte Carlo Blind Estimation algorithm (22, 23) applied to the ΔR 1 curves of tumor voxels that exhibited significant perfusion. A pixel was considered perfused if the mean ΔR 1 between the first and second contrast agent injection was higher than 2 times the standard deviation of ΔR 1 before contrast injection.
The DCE-MRI derived perfused fraction (PF) was calculated from this analysis. Multiagent curves in the perfused pixels were simultaneously fitted with the gamma capillary Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 9, 2018; DOI: 10.1158/0008-5472. CAN-17-2569 For the Hoechst staining, mice were kept anesthetized after the MRI measurement and Hoechst (8 mg/mL in saline, 32 mg/kg) was injected via the tail vein. After 3 min, mice were sacrificed by cervical dislocation. Further processing of the tumor tissue is described in the Supplementary Information. In short, the frozen tumor sections were subsequently stained for endothelial cells. Semi-automated analysis of the stained slides was performed to determine perfused vessel fractions (PF) from the Hoechst staining and vascular density (VD) from the endothelial staining. 
Results
Representative multi-agent DCE-MRI parameter maps of a DMXAA-treated and placebo-treated animal are shown in Figures 1 and 2, respectively. While the DCE-MRI parameters overall remained stable in the placebo-treated animals, substantial treatment effects were observed in the parameter maps of the DMXAA-treated animals. Both at 2 h and at 24 h after treatment a large region of the tumor was non-perfused. In the remaining perfused pixels of the tumor, substantially decreased flow was observed at 2 h and at 24 h. In addition, a pronounced increase in permeability was observed at 2 h, as expressed by an increase in the extraction fraction E of G5 and G2 and to a lesser extent in the extraction fraction of Gd-DOTA. The increase in permeability was not reflected in the K trans maps. K trans of G2 and G5 did not show visual differences in the perfused pixels upon treatment, while K trans of Gd-DOTA showed a decrease at both time points after treatment.
The mean quantitative DCE-MRI parameters of the perfused pixels at the different time points are presented in Figure 3 . In the placebo-treated animals most of the parameters did not significantly change over time, except for a mild, yet significant, decrease in F and K trans Gd-DOTA at both time points after placebo treatment (P<0.005 and P<0.016, respectively) and an increase in t c at 2 h after treatment (P=0.008). In the DMXAA- Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Discussion
In this paper, we presented the first application of a recently developed multi-agent tracer-kinetic modeling approach (19) for the assessment of tumor treatment response.
Sequential injection of different contrast agents has been employed previously for evaluation of tumor vascular properties using DCE-MRI (17, 18, (25) (26) (27) . However, in these previous studies the different injections were separately analyzed, while simultaneous modeling of the multi-agent data facilitates a comprehensive and robust assessment of tissue properties by exploiting the fact that a number of parameters can be constrained to be identical between the agents based on physiological grounds (19) .
The vascular disrupting agent DMXAA was chosen as model agent for the assessment of anti-vascular therapy. DMXAA (also known as Vadimezan and ASA404) induces a cascade of anti-vascular events in the tumor early after administration (13, 28) . Within 30 minutes after administration it induces endothelial cell apoptosis, leading to increased vascular permeability and decreased blood perfusion, resulting from loss of plasma and associated higher blood viscosity (28) . The subsequent loss of endothelial barrier causes increased vascular permeability (20) . A second mechanism of action of DMXAA is the induction of tumor necrosis factor alpha (TNFα) among other cytokines (28) . TNFα contributes to increase in vascular permeability (29) . The enhanced permeability causes an increase in interstitial pressure, which further compromises tumor blood flow (30) .
Generally, in mouse models this cascade of events completely shuts down the tumor vasculature, after a transient period of decreased blood flow and high vascular permeability. In clinical trials with DMXAA in patients the anti-vascular cascade was observed only partly, with minor increase in TNFα after DMXAA administration (13) .
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Author Manuscript Published OnlineFirst on January 9, 2018; DOI: 10.1158/0008-5472. CAN-17-2569 Because of the limited therapeutic effects in patients, the development of DMXAA has been discontinued in 2010 after unsuccessful Phase III trials, in which no effects of DMXAA on overall survival could be proven (31) . Nevertheless, DMXAA remains an interesting drug to investigate in the preclinical setting because of its well-defined antivascular effects, which can be used to investigate novel imaging methods for the characterization of tumor vasculature, as was done in the present study.
The here observed effects of treatment on DCE-MRI parameters are exactly in line with the previously described vascular events following administration of DMXAA. The rapid drop in PF, F and v b is consistent with induction of endothelial apoptosis and subsequent vascular shutdown early after administration. The increase in t c at both time points after treatment is likely related to high blood viscosity and associated low blood flow. The significant drop in α -1 after treatment is indicative of a narrower distribution of t c in the tumor pixels and a lower vascular heterogeneity. A possible explanation for this finding is that the response of blood vessels to the vascular therapy depends on the blood flow (28) . Vessels with low blood flow may be particularly sensitive to vascular disrupting agents (28) . The DMXAA may thus have particularly affected these blood vessels, leading to immediate vascular shutdown. Removal of these specific capillary paths by Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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An important result of this study is that the increase in permeability would not have been detected using only a low molecular weight contrast agent, such as Gd-DOTA, as we did not observe an increase in E Gd-DOTA at 2 h after DMXAA treatment. This finding further advocates the use of high molecular weight contrast agents for characterization of tumor vasculature (14) . Moreover, the use of differently sized contrast agents in the same acquisition can give additional insights in the vascular permeability, such as the endothelial pore size (3) . Our results also further stress that a more complete insight in vascular changes can be obtained from advanced modeling of macromolecular DCE-MRI data, compared to conventional Tofts modeling. K trans of G2 and G5 both failed to show an increase in permeability after treatment, because of the counteracting effects of decreased flow and increased permeability on K trans (10) .
In the placebo-treated control animals generally no changes in DCE-MRI parameters were observed over time, except for a decrease in F and K trans Gd-DOTA and increase in t c . The reduction in tumor perfusion may be related to the repeated anesthesia. It has previously been shown that repeated isoflurane anesthesia leads to a decreased heart rate and blood pressure in rats (32), although we have not confirmed this by monitoring of heart rate and blood pressure for the mice in this study. This systemic physiological effect of anesthesia likely also influences the local blood flow in the tumor tissue.
The histopathological results from Hoechst staining corroborated the DCE-MRI findings.
While the number of vessels was similar between DMXAA-and placebo-treated animals, Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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While we employed multi-agent tracer-kinetic modeling for assessment of vascular effects after treatment with a vascular disrupting agent, this method could also be used for evaluation of other anti-vascular therapies. The technique could be particularly useful for characterization of the dynamic effects of anti-angiogenic therapies on the tumor vasculature. Anti-angiogenic agents may induce transient normalization of the tumor vasculature, prior to vascular shutdown (33) . Vessel normalization is characterized by reduction of the abnormal tortuosity and hyperpermeability of tumor blood vessels, leading to reduced interstitial pressure and increased blood flow (34) . This transient period of vessel normalization can be exploited by combination therapies of antiangiogenic and cytotoxic agents (34) . For full efficacy of these combination therapies it is important to optimize the treatment schedule and dosing. While Tofts modeling may not be sensitive enough for detection of vessel normalization, because of the counteracting effects of higher blood flow and lower permeability on K trans , the multiagent approach, combined with a more sophisticated model of the tissue microvasculature (such as the GCTT model used here), is able to differentiate between these effects and is therefore probably more suitable for evaluation of anti-angiogenic therapies.
Whereas the application of the multi-agent tracer-kinetic modeling is mainly focused on the preclinical evaluation of tumor vasculature, it is also relevant to humans. Recently, the feasibility of clinical application of the multi-agent modeling approach has been shown in patients with (high risk of) pancreatic cancer (35) . It was shown that the multi- Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 9, 2018; DOI: 10.1158/0008-5472. CAN-17-2569 agent approach is promising for the identification of pancreatic malignancies. In that particular study, the injection protocol consisted of sequential injection of low-molecular weight gadoteridol and the iron-based nanoparticle blood pool agent ferumoxytol.
Our study had some limitations. Only one vascular therapeutic agent was evaluated.
The sensitivity of the technique to the vascular effects of other therapeutic agents needs to be assessed in future studies. In addition, the method was only tested in one animal tumor model. While we expect that the method is translatable to other animal models as well as to human applications, future studies in different cancer models are needed to further validate the use of the multi-agent tracer-kinetic modeling technique for assessment of anti-vascular therapies.
In conclusion, we have shown that multi-agent tracer-kinetic modeling can be used to accurately determine the effects of a vascular disrupting agent on the tumor vasculature. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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